Author:
Chau I,Cunningham D,Russell C,Norman A R,Kurzawinski T,Harper P,Harrison P,Middleton G,Daniels F,Hickish T,Prendeville J,Ross P J,Theis B,Hull R,Walker M,Shankley N,Kalindjian B,Murray G,Gillbanks A,Black J
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson III AB (2002) Phase III study of gemcitabine in combination with fluorouracil vs gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20: 3270–3275
2. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA (2001) Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 19: 3447–3455
3. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA (2002) A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87: 161–167
4. Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403–2413
5. Cheverton P, Friess H, Andras C, Salek T, Geddes C, Bodoky G, Valle J, Humblet Y (2004) Phase III results of exatecan (DX-8951f) vs gemcitabine (Gem) in chemotherapy-naive patients with advanced pancreatic cancer (APC). J Clin Oncol (Meeting Abstracts) 22: 314
Cited by
68 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献